CISCRP, Pharma Consortium Aim to Improve Patient Diversity in Trials
Applied Clinical Trials
CISCRP – in partnership with 10 leading pharmaceutical companies and clinical research service providers – has launched a new consortium that will focus energy and resources on community-based education to improve clinical trial diversity.
CISCRP--in partnership with ten leading pharmaceutical companies and clinical research service providers--has launched a new consortium that will resource community-based education during the next five years beginning in early 2020, to improve patient diversity in clinical trials. Consortium members include Merck, IQVIA, Biogen, Otsuka, CSL Behring, Janssen, WCG, Boston Scientific, EMD Serono, and Pfizer. Representatives from each member company will participate on a steering committee and will provide staff and resources to support the planning and execution of live educational events in five targeted urban centers annually.
